Zevra Therapeutics Inc ZVRA

$9.07 -0.21 (-2.26%)

Valuation

Market cap
552,206,000
Revenue TTM
$106,470,000
Net income TTM
$83,230,000
P/E (trailing)
5.31
P/E (forward)
10.04
Profit margin
78.17%
Debt to equity
0.00

Trading

Volume
670,300
Avg volume
974,100
Day's range
$9.00 – $9.50
Shares out
59,505,000
Stochastic %K
5%
Beta
1.01
Analysts
Strong Buy
Price target
$23.50

Price

Company profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial...

Show more

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
888 958 1253
Website
https://www.zevra.com
Address
101 Federal Street, Suite 103, Boston, United States

Latest news

Stocktwits

poctordoker Nov 20, 3:44 PM
$ZVRA when are the tutes going to come and defend against these short attacks
0 replies
Wahoos Nov 20, 3:42 PM
$ZVRA Forward PE is now 3 ex-cash.
0 replies
poctordoker Nov 20, 3:24 PM
$ZVRA crazy cheap at this price, like when we were in the 4's way back when...
0 replies
Sabre2222 Nov 20, 12:50 PM
$ZVRA lots of chatter about buyout on this board. Do you all really want neil in control when a buyout happens?
5 replies
gc358 Nov 20, 10:45 AM 0 replies
GridironGainz Nov 19, 9:50 PM 0 replies
ZVRA100 Nov 19, 7:04 PM
$ZVRA they better be working on finalizing the deal. No real catalysts left now.
1 replies
ZVRA100 Nov 19, 6:58 PM
$ZVRA fucking ridiculous
0 replies